全反式维A酸+三氧化二砷联合诱导分化治疗急性早幼粒细胞白血病

Study on the treatment of acute promyelocytic leukemia of all-trans retinoic acid plus arsenic trioxide

目的研究联合应用全反式维A酸(ATRA)+三氧化二砷(As2O3)诱导分化治疗急性早幼粒细胞白血病(APL)的疗效及毒副作用。方法初治APL患者76例,治疗组46例,均给予ATRA+As2O3诱导分化治疗,对照组30例给予ATRA诱导分化治疗,比较两组疗效及毒副作用。结果治疗组及对照组获得完全缓解(CR)时间分别为(26.2±4.0)d,(49.5±8.5)d,差异有统计学意义(P<0.05),而两组毒副作用发生率差异无统计学意义(P>0.05)。结论联合应用ATRA+As2O3诱导分化治疗APL较单纯用ATRA获得CR时间明显缩短,且毒副作用无明显增加。

Objective To compare the efficacy and adverse effects of all-trans retinoic acid （ATRA） plus arsenic trioxide（As2O3） with ATRA in the treatment of acute promyelocytic leukemia（APL）. Methods 46 patients in the treatment group were treated with ATriA combined with As2O3, 30 patients in the compare group were treated with ATRA, then compare the outcome and adverse effects between the two groups. Resuits The time achieving complete remission by ATRA combined with As2O3 is （26.2±4.0） days, but that time of patients only treated with ATRA is （49.5±8.5） days, there is significant difference （P 〈0.05）. But there is not obvious difference in the adverse effects between the two groups（P 〉0.05）. Conclusion The complete remission time of APL contracts dramaticly by administering ATRA combined with As2O3, and this regimen had lower toxic reactions.